WO2001064255A1 - Method for detecting and killing epithelial cancer cells - Google Patents

Method for detecting and killing epithelial cancer cells Download PDF

Info

Publication number
WO2001064255A1
WO2001064255A1 PCT/US2001/006318 US0106318W WO0164255A1 WO 2001064255 A1 WO2001064255 A1 WO 2001064255A1 US 0106318 W US0106318 W US 0106318W WO 0164255 A1 WO0164255 A1 WO 0164255A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
cells
marking agent
cancer cells
mitochondrial
Prior art date
Application number
PCT/US2001/006318
Other languages
French (fr)
Inventor
Samuel D. Bernal
Douglas D. Burkett
Ralph E. Green
Seth D. Rose
Original Assignee
Zila, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zila, Inc. filed Critical Zila, Inc.
Priority to JP2001563152A priority Critical patent/JP2003525044A/en
Priority to EP01916271A priority patent/EP1214101A4/en
Priority to NZ515202A priority patent/NZ515202A/en
Priority to CA002370741A priority patent/CA2370741A1/en
Priority to BR0104747-7A priority patent/BR0104747A/en
Priority to IL14614101A priority patent/IL146141A0/en
Priority to AU43316/01A priority patent/AU785489B2/en
Priority to MXPA01010886A priority patent/MXPA01010886A/en
Publication of WO2001064255A1 publication Critical patent/WO2001064255A1/en
Priority to NO20015242A priority patent/NO20015242L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to methods for detecting epithelial cancer.
  • the invention pertains to methods for selectively killing epithelial cancer cells.
  • the invention concerns methods for detecting epithelial cancer cells in the presence of normal cells and/or for selectively killing such cells, in which the mitochondria of cancer cells retain a mitochondrial marking agent for a time sufficient to permit identification and/or killing such cells.
  • Cancer or “cancerous” cells are used in the broad sense, to include invasive cancer cells, cancer-in- situ cells and severely dysplastic cells.
  • Mitochondrial marking agent means a compound that is selectively taken up by the mitochondria of living cancer cells and is selectively retained in cancer cells for a time sufficient to permit identification and/or killing or incapacitation thereof .
  • “Killing" of cells means either causing cell death s apoptosis or cell changes that render a cell incapable of reproduction and metastasizing .
  • Adduct means the reaction product, either covalent or noncovalent, of a mitochondrial marking agent and a cancer chemotherapeutic agent .
  • Adjuvant means a mitochondrial marking agent that, in combination with another chemotherapeutic agent, causes improved killing of cancer cells, either synergistically or by additive effects with the other agent.
  • In-vivo diagnostic procedures for detecting malignant and premalignant epithelial lesions or carcinomas employing dye compositions that selectively "color" tissues that are abnormal due to dysplasia, hyperplasia, tumorigenesis and other active surface lesions, are known in the art. These diagnostic methods employ a dye that imparts color to a cancerous substrate, which is then detectable under light at visible wavelengths or a fluorescent dye that imparts color to the substrate, which is then detectable when illuminated by light at wavelengths outside the visible spectrum.
  • toluidine blue selectively marks cancerous epithelial tissue because it is selectively retained in the relatively larger interstitial spaces between cancer cells
  • the mechanism of such selective staining of epithelial tissue by cationic dyes e.g., dyes such as rhodamine, fluoresceins, oxazine and thiazine dyes (including toluidine blue) and other cationic supravital marking agents, is the selective uptake and selective retention of the agent in the mitochondria of cancer cells.
  • This selective mitochondrial uptake and retention is apparently due to the higher electrical potential (negative charge on the inside of the membrane) of cancerous cells' mitochondria as compared to mitochondria of normal cells. See, e.g., Chen et al .
  • the selective marking of cancer cells by, and retention in the mitochondria of cancer cells of, supravital cationic dyes and other supravital cationic marking agents are related to one of the very characteristics of cancer cells that appears to be responsible for their rapid cloning growth and metastasizing ability, namely, that the higher electrical potential of the mitochondria of cancer cells is the source of cellular energy and is the driving force for ATP (adenosine triphosphate) production by the cells.
  • Our detection methods comprise the steps of delivering a cationic supravital mitochondrial marking agent to tissue in the locus of a suspect cancerous site on the epithelium (which contains both normal and cancerous cells) , thus causing said agent to be taken up and selectively retained in the mitochondria of the cancer cells.
  • the cancerous cells are then detectable by any suitable method, for example, instrumental or visual examination under visible light or under light of selected invisible wavelengths.
  • a rinse reagent is applied to the locus of the suspect cancerous site, thus enhancing the rate of release of the agent from the mitochondria of the normal cells and further increasing the selectivity of the diagnostic methods.
  • a method for selectively killing cancerous epithelial cells comprising the step of contacting cancerous cells in the locus of a suspect cancerous site with a cationic supravital mitochondrial marking agent, to cause cell death or to render the ' cancer cells substantially incapable of multiplication.
  • the marking agent can be delivered to the cancer cells in a single discrete dose, or continuously, or in repeated discrete doses, with or without employing a rinse reagent after each dose.
  • a method of improving the selectivity and cancer cell killing ability of cancer chemotherapeutic agents comprising the steps of either (1) forming a reaction product of a cationic supravital agent and a chemotherapeutic agent and delivering the reaction product to cancerous epithelial cells or (2) combining the cationic supravital agent with a cancer chemotherapeutic agent, to improve the selectivity or killing ability of the chemotherapeutic agent, either by additive or synergistic effects, or both.
  • cationic supravital mitochondrial marking agents include dyes, including toluidine blue 0, alcian blue, malachite green, phenosafranin, acriflavine, pyronine Y, toluylene blue and brilliant green;
  • non-dye compounds including peonidin, oxythiamine, tiemonium iodide, elliptinium acetate and furazolium chloride.
  • the preferred mitochondrial marking agents are dyes of the oxazine and thiazine class.
  • the thiazine dyes are especially preferred, particularly toluidine blue 0, Azure A, Azure B and ring-substitution and N- substitution analogs thereof.
  • the marking agent or reaction product of marking agent + chemotherapeutic agent In order to be selectively absorbed and retained in cancer cell mitochondria, the marking agent or reaction product of marking agent + chemotherapeutic agent, must have a molecular weight of below about 5,000. Further, because of marked differences in the selective marking and therapeutic activity of various closely related analogs, it appears that the molecular structure of the marking agent significantly affects its ability to selectively mark and/or kill living cancer cells in the presence of normal living cells. These differences in cell marking and killing ability are related to structural features, e.g., location and type of ring- substituents and N-substituents, of the marking agent molecules that implicate one or more or all of the following mechanisms of action:
  • the structure of the marking agent molecule e.g., position and nature of ring and N-substituents on the cationic molecule, affects the availability of the positive charge and hinders the ability of the marking agent or "stacked" groups of them to be attracted by the negative charges on the mitochondrial membranes or within the mitochondria.
  • the structure of the marking agent molecule permits it to intercalate into or "stack" along the exterior of mitochondrial DNA of cancer cells.
  • the structure of the marking agent molecule permits it or stacked groups of them to bind to specific active sites, e.g., four specific proteins, in the mitochondria, and/or precipitate with cardiolipins at the inner surface of the mitochondrial membrane.
  • the structure of the marking agent affects its reduction potential and its tendency to change to the uncharged "leuco" form. 5.
  • the structure of the marking agent affects its acidity (p a ) , and, in turn, the ability of the cationic marking agent to deprotonate at physiological pH .
  • the cationic form of the dye can be attracted to the outer surface of the mitochondrial membrane, whereupon the dye cation can lose a proton and concomitantly lose its positive charge, thereby liberating the neutral form of the dye, which may more readily penetrate the nonpolar matrix of the membrane and gain access to the interior of the mitochondrion.
  • Mechanisms 1 dye- membrane) , 2 (dye-base pair or dye-dye) , and 3 (dye- protein or dye-lipid) depend on the hydrophobicity- lipophilicity of the dye, which can be assessed by various means, one of which is the partition coefficient between aqueous solution and a low-polarity organic solvent, such as 1-octanol (i.e., log P values) .
  • Mechanisms 4 and 5 depend on hydrophobicity- lipophilicity, due to the effect of differential solvation of reactant and product on reduction potential (oxidized vs. reduced forms) and p a (neutral vs. charged forms) .
  • hydrophobicity hampers the solvation of protonated tertiary aliphatic amines (R 3 NH + ) , thereby decreasing their acidity relative to secondary amines (R 2 NH 2 + ) .
  • a cationic supravital marking agent having a log P of from about -1.0 to about 5.
  • Different concentrations of the various cationic marking agents at 100, 50, 10 and 1 ⁇ g/ml are prepared in RPMI medium complete with 20% fetal calf serum, 1 mM glutamine, hydrocortisone, insulin, transferrin, estradiol, selenium and growth hormone.
  • the carcinoma cells are incubated at 37EC in tissue culture incubators with 5% C0 2 and 95% relative humidity, for 5 minutes with each agent and concentration there and then rinsed twice using 2 minute incubations with 1% acetic acid. After incubation and rinsing, the cells are harvested, at 30 min., 1 hour, 2 hours, 4 hours and 8 hours. The cells are then extracted with 2-butanol and analyzed by spectrophotometry for quantitation of the marking agent.
  • the results show that there is a concentration dependence in the rate of accumulation of marking agent in the mitochondria of both carcinoma and normal cells and in the selectivity of release of the marking agent from cancer cells, but this concentration dependence starts to become less pronounced.
  • the saturation concentration for toluidine blue 0 occurs at concentrations of lO ⁇ g/ml and above.
  • the saturation concentrations for the other marking agents are similarly determined.
  • the remaining experiments are conducted with a concentration of lO ⁇ g/ml for toluidine blue 0 and at the saturation concentrations for the other marking agents so-determined, unless stated otherwise.
  • the mitochondrial localization of the agents is analyzed using confocal high resolution microscopy and phase contrast microscopy.
  • Living cells are cultivated in complete growth medium with 20% fetal calf serum and growth factors, and maintained at 37EC. These cells accumulate and retain the marking agents in the mitochondria. When these cells are then maintained in an agent-free medium, carcinoma cells retain the agent for longer than about 1 hour, but normal epithelial cells release the agent within about 15 minutes.
  • Known agents that alter the mitochondrial electrical potential are used to pretreat epithelial cancer cells, followed by treatment with the cationic supravital mitochondrial marking agents.
  • These pretreatment agents include azide and cyanide preparations and dinitrophenol.
  • Epithelial cancer cells are also pre-stained with the various dyes and then are post-treated with these known agents.
  • the release of the dyes from the cells or the transfer of the dyes to other subcellular compartments, including the nucleus is analyzed.
  • the cells pretreated with these agents do not accumulate dyes in the mitochondria and the mitochondria of the pre-stained cells release the dye upon post- treatment with these agents.
  • Fresh explants of resected epithelial carcinomas are analyzed for marking agent uptake and retention. After resection, the carcinomas are microdissected from surrounding tissue, cut into 3 mm sections and maintained as explant tissue cultures at 37°C. These explants are then incubated with the various agents and then extracted for quantitation of the agent.
  • Oral carcinoma have rapid uptake and prolonged retention of these agents.
  • the agents start to be released from the cells after about one hour of cultivation in agent-free medium. However, the agents are released faster when the cells are incubated in medium that does not contain growth factors, fetal calf serum and other medium additives. The agents are also released faster when the cells are grown in adverse conditions such as lower temperatures.
  • SqCHN Oral carcinoma
  • normal epithelial cells quickly release the agents from their mitochondria and from the cell much more quickly. By 10-15 minutes, most of the agent is released from the mitochondria.
  • the following adducts of cationic mitochondrial marking agents and various known chemotherapeutic agents are employed, with substantially similar results, except that the cancer cell kill rate and selectivity of the chemotherapeutic agent are substantially improved.
  • a toluidine blue drug substance is prepared in accordance with the manufacturing procedures disclose in the U.S. Patent 6,086,852, issued to Burkett on July 11, 2000. Components of the drug substance are then fractionated and separated by semi-preparative HPLC, yielding the analogs identified in the ⁇ 852 patent as represented by Peaks 5, 6, 7 and 8.
  • the compounds represented by peaks 7 and 8 are toluidine blue regioisomers, having the ring methyl group in the -2 position (peak 8) and the -4 position (peak 7) .
  • the compound represented by peak 5 is the N-demethylated derivative of peak 7 and the compound represented by peak 6 is the N-demethylated derivative of peak 8.
  • the compounds represented by peaks 5, 6, 7 and 8, obtained during the fractionation of the toluidine blue O, are analyzed for their selective toxicity towards living oral carcinoma cells (SqCHN) compared to living normal oral epithelial cells.
  • SqCHN living oral carcinoma cells
  • Separate cultures of squamous carcinoma cells and normal epithelial cells are incubated with the different dye fractions and then washed with dye-free medium. The cells are then re- incubated in growth medium and observed over a period of 8 days to determine the extent of cell killing.
  • the compound of peak 6 results in 95% cell death of carcinoma cells, compared to only about 20% killing of normal cells.
  • the compound of peak 8 shows 89% cell death of carcinoma cells whereas it only causes about 20% killing of normal cells.
  • the selective retention of the compounds of peaks 6 and 8 is selectively toxic towards carcinoma cells.
  • the selective introduction into the mitochondria of cationic dyes leads to disruption of the mitochondrial electrical potential which is the source of cellular energy and the driving force of ATP (adenosine triphosphate) production of the cells.
  • ATP adenosine triphosphate
  • the therapeutic characteristics of the compounds of peaks 6 and 8 are determined by further in-vi tro tests, conducted in the manner of Example 8, using other isolates of carcinoma cells and normal epithelial cells.
  • the testing profile includes other squamous carcinomas of the head and neck, esophagus, lung, cervix and skin, as well as other types of cancers, including adenocarcinomas, lymphomas and sarcomas.
  • In-vivo "delay of tumor growth” and "tumor regression assay” tests using tumor-bearing animals, including head and neck and lung carcinomas implanted in Balb-C mice, are made to analyze the in-vivo therapeutic benefit of these compounds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A diagnostic method for detecting cancerous epithelial cells by selectively marking the mitochondria of the cancer cells, by delivering to the epithelium a cationic supravital mitochondrial marking agent. Selective killing of cancerous epithelial cells in the presence of normal cells is effected by delivering a cationic supravital mitochondrial marking agent to epithelial cancer cells. The killing agent can also comprise the reaction product of the marking agent and a cancer chemotherapeutic drug or in admixture with drug.

Description

METHOD FOR DETECTING AND KILLING EPITHELIAL CANCER CELLS
Related Application
This application is a continuation-in-part of copending International Application, PCT/US00/05387 , filed February 28, 2000, entitled "Method of Detecting and Killing Epitheleal Cancer Cells.
Field of the Invention
This invention relates to methods for detecting epithelial cancer.
In another respect the invention pertains to methods for selectively killing epithelial cancer cells.
In a further aspect, the invention concerns methods for detecting epithelial cancer cells in the presence of normal cells and/or for selectively killing such cells, in which the mitochondria of cancer cells retain a mitochondrial marking agent for a time sufficient to permit identification and/or killing such cells. Definitions
As used herein, the following terms have the indicated meanings:
"Cancer" or "cancerous" cells are used in the broad sense, to include invasive cancer cells, cancer-in- situ cells and severely dysplastic cells.
"Mitochondrial marking agent" means a compound that is selectively taken up by the mitochondria of living cancer cells and is selectively retained in cancer cells for a time sufficient to permit identification and/or killing or incapacitation thereof .
"Killing" of cells means either causing cell deaths apoptosis or cell changes that render a cell incapable of reproduction and metastasizing .
"Adduct" means the reaction product, either covalent or noncovalent, of a mitochondrial marking agent and a cancer chemotherapeutic agent .
"Adjuvant" means a mitochondrial marking agent that, in combination with another chemotherapeutic agent, causes improved killing of cancer cells, either synergistically or by additive effects with the other agent.
Background of the Invention
In-vivo diagnostic procedures for detecting malignant and premalignant epithelial lesions or carcinomas, employing dye compositions that selectively "color" tissues that are abnormal due to dysplasia, hyperplasia, tumorigenesis and other active surface lesions, are known in the art. These diagnostic methods employ a dye that imparts color to a cancerous substrate, which is then detectable under light at visible wavelengths or a fluorescent dye that imparts color to the substrate, which is then detectable when illuminated by light at wavelengths outside the visible spectrum.
For example, procedures employing fluorescein and fluorescein derivatives are disclosed in Chenz, Chinese Journal of Stomatology (27:44-47 (1992)) and Filurin (Stomatologiia (Russian) 72:44-47 (1993)). These procedures involve application of the dye, followed by examination under ultraviolet light to detect the cancerous/precancerous tissue, which is selectively fluorescent. Another prior art procedure involves rinsing the epithelium with toluidine blue, followed by normal visual examination to detect any selectively stained tissue. Such procedures are disclosed, for example in the patents to Burkett (U.S. 6,086,852), Tucci (U.S. 5,372,801) and Mashberg (U.S. 4,321,251). Use of other thiazine dyes and oxazine dyes in an analogous manner is disclosed in U.S. Patent 5,882,627 to Pomerantz .
Heretofore, it was theorized that such dyes selectively "marked" cancerous tissue because the dye was retained in the relatively larger interstitial spaces between the cells of cancerous tissue and would not efficiently penetrate the tighter intracellular junctions of normal tissue or be selectively retained in such relatively smaller spaces.
Contrary to the belief that toluidine blue selectively marks cancerous epithelial tissue because it is selectively retained in the relatively larger interstitial spaces between cancer cells, the mechanism of such selective staining of epithelial tissue by cationic dyes, e.g., dyes such as rhodamine, fluoresceins, oxazine and thiazine dyes (including toluidine blue) and other cationic supravital marking agents, is the selective uptake and selective retention of the agent in the mitochondria of cancer cells. This selective mitochondrial uptake and retention is apparently due to the higher electrical potential (negative charge on the inside of the membrane) of cancerous cells' mitochondria as compared to mitochondria of normal cells. See, e.g., Chen et al . , Cancer Cells 1/The Transformed Phenotype, 75-85 (Cold Spring Harbor Laboratory, 1984); Lampidis, et al . , Cancer Research 43, 716-720 (1983). In fact, the selective marking of cancer cells by, and retention in the mitochondria of cancer cells of, supravital cationic dyes and other supravital cationic marking agents, are related to one of the very characteristics of cancer cells that appears to be responsible for their rapid cloning growth and metastasizing ability, namely, that the higher electrical potential of the mitochondria of cancer cells is the source of cellular energy and is the driving force for ATP (adenosine triphosphate) production by the cells.
Summary of the Invention
We have now discovered a method for in-vivo detection of cancerous epithelial cells by selective marking of the mitochondria thereof.
In another respect, we have discovered a therapeutic method for selectively killing cancer cells in the presence of normal cells.
Our detection methods comprise the steps of delivering a cationic supravital mitochondrial marking agent to tissue in the locus of a suspect cancerous site on the epithelium (which contains both normal and cancerous cells) , thus causing said agent to be taken up and selectively retained in the mitochondria of the cancer cells. The cancerous cells are then detectable by any suitable method, for example, instrumental or visual examination under visible light or under light of selected invisible wavelengths.
In a further embodiment, after the marking agent is taken up by the mitochondria, a rinse reagent is applied to the locus of the suspect cancerous site, thus enhancing the rate of release of the agent from the mitochondria of the normal cells and further increasing the selectivity of the diagnostic methods.
According to another important embodiment of the invention, we provide a method for selectively killing cancerous epithelial cells comprising the step of contacting cancerous cells in the locus of a suspect cancerous site with a cationic supravital mitochondrial marking agent, to cause cell death or to render the ' cancer cells substantially incapable of multiplication. The marking agent can be delivered to the cancer cells in a single discrete dose, or continuously, or in repeated discrete doses, with or without employing a rinse reagent after each dose.
In a further embodiment of the invention, we provide a method of improving the selectivity and cancer cell killing ability of cancer chemotherapeutic agents comprising the steps of either (1) forming a reaction product of a cationic supravital agent and a chemotherapeutic agent and delivering the reaction product to cancerous epithelial cells or (2) combining the cationic supravital agent with a cancer chemotherapeutic agent, to improve the selectivity or killing ability of the chemotherapeutic agent, either by additive or synergistic effects, or both.
These, other and further embodiments of the invention will be apparent to those skilled in the art and a better understanding of the invention will be obtained from the following examples which are provided to illustrate the invention and not as indications of the scope thereof, which is defined only by the appended claims .
In the practice of the invention and in the following working examples, cationic supravital mitochondrial marking agents, include dyes, including toluidine blue 0, alcian blue, malachite green, phenosafranin, acriflavine, pyronine Y, toluylene blue and brilliant green;
and
"non-dye" compounds, including peonidin, oxythiamine, tiemonium iodide, elliptinium acetate and furazolium chloride.
According to the presently preferred embodiment of the invention, the preferred mitochondrial marking agents are dyes of the oxazine and thiazine class. The thiazine dyes are especially preferred, particularly toluidine blue 0, Azure A, Azure B and ring-substitution and N- substitution analogs thereof.
In order to be selectively absorbed and retained in cancer cell mitochondria, the marking agent or reaction product of marking agent + chemotherapeutic agent, must have a molecular weight of below about 5,000. Further, because of marked differences in the selective marking and therapeutic activity of various closely related analogs, it appears that the molecular structure of the marking agent significantly affects its ability to selectively mark and/or kill living cancer cells in the presence of normal living cells. These differences in cell marking and killing ability are related to structural features, e.g., location and type of ring- substituents and N-substituents, of the marking agent molecules that implicate one or more or all of the following mechanisms of action:
1. The structure of the marking agent molecule, e.g., position and nature of ring and N-substituents on the cationic molecule, affects the availability of the positive charge and hinders the ability of the marking agent or "stacked" groups of them to be attracted by the negative charges on the mitochondrial membranes or within the mitochondria.
2. The structure of the marking agent molecule permits it to intercalate into or "stack" along the exterior of mitochondrial DNA of cancer cells.
3. The structure of the marking agent molecule permits it or stacked groups of them to bind to specific active sites, e.g., four specific proteins, in the mitochondria, and/or precipitate with cardiolipins at the inner surface of the mitochondrial membrane.
. The structure of the marking agent affects its reduction potential and its tendency to change to the uncharged "leuco" form. 5. The structure of the marking agent affects its acidity (p a) , and, in turn, the ability of the cationic marking agent to deprotonate at physiological pH . Thus, the cationic form of the dye can be attracted to the outer surface of the mitochondrial membrane, whereupon the dye cation can lose a proton and concomitantly lose its positive charge, thereby liberating the neutral form of the dye, which may more readily penetrate the nonpolar matrix of the membrane and gain access to the interior of the mitochondrion.
The intermolecular interactions of mechanisms 1 dye- membrane) , 2 (dye-base pair or dye-dye) , and 3 (dye- protein or dye-lipid) depend on the hydrophobicity- lipophilicity of the dye, which can be assessed by various means, one of which is the partition coefficient between aqueous solution and a low-polarity organic solvent, such as 1-octanol (i.e., log P values) . Mechanisms 4 and 5 depend on hydrophobicity- lipophilicity, due to the effect of differential solvation of reactant and product on reduction potential (oxidized vs. reduced forms) and p a (neutral vs. charged forms) . For example, hydrophobicity hampers the solvation of protonated tertiary aliphatic amines (R3NH+) , thereby decreasing their acidity relative to secondary amines (R2NH2 +) . According to the presently preferred embodiment of the invention, one employs a cationic supravital marking agent having a log P of from about -1.0 to about 5.
The following examples are presented to enable those skilled in the art to understand and practice the invention and to identify the presently preferred embodiment. These examples are for illustrative purposes only are not intended to limit the scope of the invention, which is defined only by the appended claims.
Example 1
Uptake and Retention of Mitochondrial Marking Agents in Living Carcinoma Cells
Different concentrations of the various cationic marking agents, at 100, 50, 10 and 1 μg/ml are prepared in RPMI medium complete with 20% fetal calf serum, 1 mM glutamine, hydrocortisone, insulin, transferrin, estradiol, selenium and growth hormone.
The carcinoma cells are incubated at 37EC in tissue culture incubators with 5% C02 and 95% relative humidity, for 5 minutes with each agent and concentration there and then rinsed twice using 2 minute incubations with 1% acetic acid. After incubation and rinsing, the cells are harvested, at 30 min., 1 hour, 2 hours, 4 hours and 8 hours. The cells are then extracted with 2-butanol and analyzed by spectrophotometry for quantitation of the marking agent.
The results show that there is a concentration dependence in the rate of accumulation of marking agent in the mitochondria of both carcinoma and normal cells and in the selectivity of release of the marking agent from cancer cells, but this concentration dependence starts to become less pronounced. The saturation concentration for toluidine blue 0 occurs at concentrations of lOμg/ml and above. The saturation concentrations for the other marking agents are similarly determined. The remaining experiments are conducted with a concentration of lOμg/ml for toluidine blue 0 and at the saturation concentrations for the other marking agents so-determined, unless stated otherwise.
Example 2 Mitochondrial Localization of the Agents in Living Cells
After incubation and rinsing of various cell lines, using the different cationic marking agents, the mitochondrial localization of the agents is analyzed using confocal high resolution microscopy and phase contrast microscopy.
Living cells, are cultivated in complete growth medium with 20% fetal calf serum and growth factors, and maintained at 37EC. These cells accumulate and retain the marking agents in the mitochondria. When these cells are then maintained in an agent-free medium, carcinoma cells retain the agent for longer than about 1 hour, but normal epithelial cells release the agent within about 15 minutes.
In contrast to living cells, dead cells or cells treated with agents that dissipate the mitochondrial membrane potential lose mitochondrial staining and accumulate the agents in the nucleus.
Example 3
Release of the Agents from Mitochondria With Dissipation of the Mitochondrial Membrane Potential
Known agents that alter the mitochondrial electrical potential are used to pretreat epithelial cancer cells, followed by treatment with the cationic supravital mitochondrial marking agents. These pretreatment agents include azide and cyanide preparations and dinitrophenol.
Epithelial cancer cells are also pre-stained with the various dyes and then are post-treated with these known agents. The release of the dyes from the cells or the transfer of the dyes to other subcellular compartments, including the nucleus is analyzed. The cells pretreated with these agents do not accumulate dyes in the mitochondria and the mitochondria of the pre-stained cells release the dye upon post- treatment with these agents.
Example 4 Tissue Explants of Sguamous Carcinomas
Fresh explants of resected epithelial carcinomas are analyzed for marking agent uptake and retention. After resection, the carcinomas are microdissected from surrounding tissue, cut into 3 mm sections and maintained as explant tissue cultures at 37°C. These explants are then incubated with the various agents and then extracted for quantitation of the agent.
Oral carcinoma (SqCHN) have rapid uptake and prolonged retention of these agents. The agents start to be released from the cells after about one hour of cultivation in agent-free medium. However, the agents are released faster when the cells are incubated in medium that does not contain growth factors, fetal calf serum and other medium additives. The agents are also released faster when the cells are grown in adverse conditions such as lower temperatures. Example 5
Tissue Explants of Normal Epithelial Cells
Cells obtained surgically from normal areas of the oral epithelium are cultivated as normal epithelial cultures. These cultures are then incubated with the marking agents for analysis of the agent uptake and retention .
Unlike the carcinoma cells, normal epithelial cells quickly release the agents from their mitochondria and from the cell much more quickly. By 10-15 minutes, most of the agent is released from the mitochondria.
Example 6 Marking Agent-Chemotherapeutic Agent Adducts
In place of the agents of Examples 1-5, the following adducts of cationic mitochondrial marking agents and various known chemotherapeutic agents are employed, with substantially similar results, except that the cancer cell kill rate and selectivity of the chemotherapeutic agent are substantially improved.
Marking Agent Chemotherapeutic Agent toluidine blue 0 methotrexate rhodamine 123 nitrogen mustard Example 7
Adjuvant Compositions
The following combinations of known cancer chemotheraputants with mitochondrial marking agents exhibit synergistic or at least additive cancer cell killing effects:
Chemotherapeutant Cationic Marking Agent
taxol toluidine blue taxotere azure A vincristin alcian blue
Selective Therapeutic Effects
In the following examples, a toluidine blue drug substance is prepared in accordance with the manufacturing procedures disclose in the U.S. Patent 6,086,852, issued to Burkett on July 11, 2000. Components of the drug substance are then fractionated and separated by semi-preparative HPLC, yielding the analogs identified in the λ852 patent as represented by Peaks 5, 6, 7 and 8. The compounds represented by peaks 7 and 8 are toluidine blue regioisomers, having the ring methyl group in the -2 position (peak 8) and the -4 position (peak 7) . The compound represented by peak 5 is the N-demethylated derivative of peak 7 and the compound represented by peak 6 is the N-demethylated derivative of peak 8.
Example 8
The compounds represented by peaks 5, 6, 7 and 8, obtained during the fractionation of the toluidine blue O, are analyzed for their selective toxicity towards living oral carcinoma cells (SqCHN) compared to living normal oral epithelial cells. Separate cultures of squamous carcinoma cells and normal epithelial cells are incubated with the different dye fractions and then washed with dye-free medium. The cells are then re- incubated in growth medium and observed over a period of 8 days to determine the extent of cell killing. The compound of peak 6 results in 95% cell death of carcinoma cells, compared to only about 20% killing of normal cells. The compound of peak 8 shows 89% cell death of carcinoma cells whereas it only causes about 20% killing of normal cells. Thus, the selective retention of the compounds of peaks 6 and 8 is selectively toxic towards carcinoma cells.
The selective introduction into the mitochondria of cationic dyes leads to disruption of the mitochondrial electrical potential which is the source of cellular energy and the driving force of ATP (adenosine triphosphate) production of the cells. The ability of carcinoma cells to divide rapidly and to metastasize is dependent upon the availability of this higher energy source .
However, effects on electric charge do not appear to be the only mechanism involved, because the compounds represented by peak 5 and peak 7 also are cationic dyes and yet they do not exhibit the same selective toxicity towards carcinomas that Peak 6 and Peak 8 demonstrate. Thus, the compounds of peaks 6 and 8 appear to have other molecular properties that lead to their selective toxicity towards carcinoma cells.
Example 9
The therapeutic characteristics of the compounds of peaks 6 and 8 are determined by further in-vi tro tests, conducted in the manner of Example 8, using other isolates of carcinoma cells and normal epithelial cells. The testing profile includes other squamous carcinomas of the head and neck, esophagus, lung, cervix and skin, as well as other types of cancers, including adenocarcinomas, lymphomas and sarcomas. In-vivo "delay of tumor growth" and "tumor regression assay" tests using tumor-bearing animals, including head and neck and lung carcinomas implanted in Balb-C mice, are made to analyze the in-vivo therapeutic benefit of these compounds. These further in vi tro and in-vivo tests confirm the selective toxicity of the compounds of peaks 6 and 8 to the wider variety of cancer cell types.
Having described the invention in such manner as to enable those skilled in the art to understand and practice it and, having identified the presently preferred embodiments thereof, WE CLAIM:

Claims

1. A diagnostic method for in vivo detection of cancerous epithelial cells by selective marking of the mitochondria thereof, comprising the step of delivering to the epithelium a cationic supravital mitochondrial marking agent.
2. A method for selective killing of epithelial cancer cells comprising the step of delivering to epithelial cancer cells a cationic supravital mitochondrial marking agent.
3. The method of claim 2 in which the agent is the reaction product of a cationic supravital mitochondrial marking agent and a cancer chemotherapeutic drug.
4. The method of claim 2 in which the agent is delivered to epithelial cancer cells in combination with another cancer chemotherapeutic drug that selectively kills cancer cells by a different mechanism than the mechanism by which the agent kills cancer cells.
5. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a molecular structure that does not hinder attraction of the positive charge of the marking agent molecule by the negative charges on the mitochondrial membranes.
6 The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a molecular structure that permits the marking agent to bind to a specific site in the mitochondria .
7. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a structure that will intercalate into or stack along the mitochondrial DNA.
8. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a molecular structure that affects its reduction potential to permit it to change to the uncharged leuco form prior to, during, or after entry into the mitochondria.
9. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent is selected to provide a molecular structure that will deprotonate at physiological pH .
10. The methods of claims 1 or 2, in which the cationic supravital mitochondrial marking agent has a log P of 0-5.
PCT/US2001/006318 2000-02-28 2001-02-27 Method for detecting and killing epithelial cancer cells WO2001064255A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2001563152A JP2003525044A (en) 2000-02-28 2001-02-27 Methods for detecting and eliminating epithelial cancer cells
EP01916271A EP1214101A4 (en) 2000-02-28 2001-02-27 Method for detecting and killing epithelial cancer cells
NZ515202A NZ515202A (en) 2000-02-28 2001-02-27 Method for detecting and killing epithelial cancer cells
CA002370741A CA2370741A1 (en) 2000-02-28 2001-02-27 Method for detecting and killing epithelial cancer cells
BR0104747-7A BR0104747A (en) 2000-02-28 2001-02-27 Use of cationic supravital mitochondrial marking agent in the detection and extinction of cancerous epithelial cells
IL14614101A IL146141A0 (en) 2000-02-28 2001-02-27 Method for detecting and killing epithelial cancer cells
AU43316/01A AU785489B2 (en) 2000-02-28 2001-02-27 Method for detecting and killing epithelial cancer cells
MXPA01010886A MXPA01010886A (en) 2000-02-28 2001-02-27 Method for detecting and killing epithelial cancer cells.
NO20015242A NO20015242L (en) 2000-02-28 2001-10-26 Method for detecting and killing epithelial cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2000/005387 WO2001064110A1 (en) 2000-02-28 2000-02-28 Method for detecting and killing epithelial cancer cells
USPCT/US00/05387 2000-02-28

Publications (1)

Publication Number Publication Date
WO2001064255A1 true WO2001064255A1 (en) 2001-09-07

Family

ID=21741108

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/005387 WO2001064110A1 (en) 2000-02-28 2000-02-28 Method for detecting and killing epithelial cancer cells
PCT/US2001/006318 WO2001064255A1 (en) 2000-02-28 2001-02-27 Method for detecting and killing epithelial cancer cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005387 WO2001064110A1 (en) 2000-02-28 2000-02-28 Method for detecting and killing epithelial cancer cells

Country Status (14)

Country Link
EP (1) EP1214101A4 (en)
JP (1) JP2003525044A (en)
KR (2) KR20080080681A (en)
CN (1) CN100544770C (en)
AU (2) AU2000237154A1 (en)
BR (1) BR0104747A (en)
CA (1) CA2370741A1 (en)
CZ (1) CZ20013861A3 (en)
IL (1) IL146141A0 (en)
MX (1) MXPA01010886A (en)
NO (1) NO20015242L (en)
NZ (1) NZ515202A (en)
RU (1) RU2226404C2 (en)
WO (2) WO2001064110A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501982A (en) * 2000-06-30 2004-01-22 ジラ・インク Rhodamine diagnostics and diagnostic methods for the detection of epithelial cancer
US6890571B2 (en) 2002-05-14 2005-05-10 National Starch And Chemical Investment Holding Corporation Slowly digestible starch product
EP1534346A2 (en) * 2002-06-04 2005-06-01 Zila Inc. Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
US6929817B2 (en) 2002-05-14 2005-08-16 National Starch & Chemical Investment Holding Corporation Slowly digestible starch product
US7081261B2 (en) * 2002-05-14 2006-07-25 National Starch And Chemical Investment Holding Corporation Resistant starch prepared by isoamylase debranching of low amylose starch
EP3932410A1 (en) 2009-07-15 2022-01-05 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064110A1 (en) * 2000-02-28 2001-09-07 Zila, Inc. Method for detecting and killing epithelial cancer cells
EP1322339A4 (en) * 2000-09-26 2004-05-26 Zila Inc Method for early prediction of the onset of invasive cancer
CA2457907A1 (en) * 2001-12-14 2003-09-04 Zila, Inc. Stain-directed molecular analysis for cancer prognosis and diagnosis
WO2006041458A1 (en) * 2004-09-30 2006-04-20 Zila Biotechnology, Inc. Light-directed method for detecting and aiding further evaluation of abnormal mucosal tissue
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
CN105510321A (en) * 2011-12-29 2016-04-20 闫文广 Detection agent composition for epithelial tissue tumor cells and preparing method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194373A (en) * 1985-06-06 1993-03-16 Thomas Jefferson University Method of determining endothelial cell coverage of a prosthetic surface
US5372801A (en) * 1991-10-31 1994-12-13 Ctm Associates, Inc. Biological stain composition, method of preparation and method of use for delineation of epithelial cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321251A (en) * 1979-12-19 1982-03-23 The United States Of America As Represented By The Department Of Health And Human Services Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse
US4816395A (en) * 1985-12-19 1989-03-28 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
EP0814847B1 (en) * 1996-01-16 2003-11-05 Zila, Inc. Methods and compositions for in-vivo detection of oral cancers and precancerous conditions
US6086852A (en) * 1997-11-13 2000-07-11 Zila, Inc. In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue
KR20010110310A (en) * 1998-12-23 2001-12-12 로저 에이. 윌리암스 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2001064110A1 (en) * 2000-02-28 2001-09-07 Zila, Inc. Method for detecting and killing epithelial cancer cells
IL148429A0 (en) * 2000-07-20 2002-09-12 Zila Inc Improved diagnostic method for detecting dysplastic epithelial tissue
EP1322339A4 (en) * 2000-09-26 2004-05-26 Zila Inc Method for early prediction of the onset of invasive cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194373A (en) * 1985-06-06 1993-03-16 Thomas Jefferson University Method of determining endothelial cell coverage of a prosthetic surface
US5372801A (en) * 1991-10-31 1994-12-13 Ctm Associates, Inc. Biological stain composition, method of preparation and method of use for delineation of epithelial cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERNAL S.D.: "Anticarcinoma activity in vivo of Rhodamine 123, a mitochondrial-specific dye", SCIENCE, vol. 222, 14 October 1983 (1983-10-14), pages 169 - 171, XP002928206 *
See also references of EP1214101A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501982A (en) * 2000-06-30 2004-01-22 ジラ・インク Rhodamine diagnostics and diagnostic methods for the detection of epithelial cancer
US6890571B2 (en) 2002-05-14 2005-05-10 National Starch And Chemical Investment Holding Corporation Slowly digestible starch product
US6929817B2 (en) 2002-05-14 2005-08-16 National Starch & Chemical Investment Holding Corporation Slowly digestible starch product
US7081261B2 (en) * 2002-05-14 2006-07-25 National Starch And Chemical Investment Holding Corporation Resistant starch prepared by isoamylase debranching of low amylose starch
AU2003204157B2 (en) * 2002-05-14 2007-08-30 Brunob Ii B.V. Resistant starch prepared by isoamylase debranching of low amylose starch
EP1534346A2 (en) * 2002-06-04 2005-06-01 Zila Inc. Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
JP2005535605A (en) * 2002-06-04 2005-11-24 ジラ バイオテクノロジー・インク Toluidine blue O drug and its in vivo staining of dysplastic tissue and its use in chemotherapy treatment
EP1534346A4 (en) * 2002-06-04 2007-07-25 Zila Inc Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
EP3932410A1 (en) 2009-07-15 2022-01-05 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system

Also Published As

Publication number Publication date
NO20015242L (en) 2001-11-29
NZ515202A (en) 2003-05-30
IL146141A0 (en) 2002-07-25
EP1214101A4 (en) 2005-04-13
CN100544770C (en) 2009-09-30
NO20015242D0 (en) 2001-10-26
CA2370741A1 (en) 2001-09-07
KR20020000222A (en) 2002-01-05
EP1214101A1 (en) 2002-06-19
AU785489B2 (en) 2007-11-15
BR0104747A (en) 2002-09-17
CN1365288A (en) 2002-08-21
JP2003525044A (en) 2003-08-26
KR100907122B1 (en) 2009-07-09
WO2001064110A1 (en) 2001-09-07
RU2226404C2 (en) 2004-04-10
AU4331601A (en) 2001-09-12
KR20080080681A (en) 2008-09-04
MXPA01010886A (en) 2002-05-06
CZ20013861A3 (en) 2002-08-14
AU2000237154A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
Han et al. A ratiometric fluorescent probe for imaging and quantifying anti-apoptotic effects of GSH under temperature stress
Leonidova et al. Photo-induced uncaging of a specific Re (I) organometallic complex in living cells
AU785489B2 (en) Method for detecting and killing epithelial cancer cells
HU228208B1 (en) Palladium-substituted bacteriochlorophyll derivatives and use thereof
Basu et al. Biological Evaluation of the NIR‐Emissive Ruby Analogue [Cr (ddpd) 2][BF4] 3 as a Photodynamic Therapy Photosensitizer
Bellin et al. Dye-sensitized photoinactivation of tumor cells in vitro
Wawi et al. Peptide Vectors Carry Pyrene to Cell Organelles Allowing Real‐Time Quantification of Free Radicals in Mitochondria by Time‐Resolved Fluorescence Microscopy
Zhong et al. Nucleus-localized platinum (II)–triphenylamine complexes as potent photodynamic anticancer agents
Burger et al. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311
Zhang et al. A benzothiophene-quinoline-based targetable fluorescent chemosensor for detection of viscosity and mitochondrial imaging in live cells
US6649144B1 (en) Method for detecting and killing epithelial cancer cells
US20030017158A1 (en) Method for detecting and killing epithelial cancer cells
Chan et al. Photodynamic activity of a glucoconjugated silicon (IV) phthalocyanine on human colon adenocarcinoma
Vuong et al. Hypericin incorporation and localization in fixed HeLa cells for various conditions of fixation and incubation
Nazarova et al. 13, 15-N-cycloimide derivatives of chlorin p6 with isonicotinyl substituent are photosensitizers targeted to lysosomes
Badary et al. Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice
Horobin Xanthenes
Vashishtha et al. Application of fluorescence microscopy to measure apoptosis in Jurkat T cells after treatment with a new investigational anticancer agent (NC 1213)
RU2713151C1 (en) Conjugate of a fluorescent dye with a peptide substance which contains a psma-binding ligand based on a urea derivative for visualizing cells expressing psma, a method for production thereof and use thereof
BRPI0612367A2 (en) cell or tissue labeling solution, kit, method of ex vivo cell or tissue labeling, use of an in vitro solution and method of diagnosing cancer or dysplasia
Bertolesi et al. Cytochemical application of tris (2, 2'-bipyridine) ruthenium (II): fluorescence reaction with sulfated polyanions of mast cell granules.
Hösli et al. Monoamine-containing neurones in cultures of rat brain stem
Buchanan et al. Intracellular accumulation of a fluorescent derivative of paromomycin in human fibroblasts
Sharma et al. Photodynamic action of merocyanine 540 on carcinoma of cervix cells
Schmid et al. Differential uptake of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea and doxorubicin by Lewis lung carcinoma and Ridgway osteogenic sarcoma

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 01800660.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NO NZ PL RO SG SK TR UA US ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00982/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2370741

Country of ref document: CA

Ref document number: 2370741

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2001 563152

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-3861

Country of ref document: CZ

Ref document number: PA/a/2001/010886

Country of ref document: MX

Ref document number: 1020017013731

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 515202

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001916271

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 43316/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10019494

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001916271

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2001-3861

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020087020377

Country of ref document: KR